BioMarin Secures Major Debt Financing for Amicus Acquisition
TipRanks (Thu, 29-Jan 4:56 PM ET)
BioMarin prices $850M senior notes, completes $2B term loan syndication
Seeking Alpha News (Thu, 29-Jan 4:15 PM ET)
PRNewswire (Thu, 29-Jan 4:05 PM ET)
Market Chameleon (Mon, 26-Jan 3:15 AM ET)
PRNewswire (Mon, 26-Jan 7:45 AM ET)
BioMarin Appoints Arpit Dav Chief Digital and Information Officer
PRNewswire (Mon, 12-Jan 4:05 PM ET)
PRNewswire (Thu, 8-Jan 4:05 PM ET)
Veeva and BioMarin Form Long-Term Strategic Partnership
PRNewswire (Thu, 8-Jan 8:30 AM ET)
Business Wire (Fri, 26-Dec 3:28 PM ET)
Market Chameleon (Fri, 19-Dec 5:32 AM ET)
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
Biomarin Pharmaceutical trades on the NASDAQ stock market under the symbol BMRN.
As of February 2, 2026, BMRN stock price climbed to $57.95 with 1,690,782 million shares trading.
BMRN has a beta of 0.69, meaning it tends to be less sensitive to market movements. BMRN has a correlation of 0.14 to the broad based SPY ETF.
BMRN has a market cap of $11.13 billion. This is considered a Large Cap stock.
Last quarter Biomarin Pharmaceutical reported $776 million in Revenue and $.12 earnings per share. This fell short of revenue expectation by $-6 million and missed earnings estimates by -$.39.
In the last 3 years, BMRN traded as high as $116.86 and as low as $50.76.
The top ETF exchange traded funds that BMRN belongs to (by Net Assets): VTI, IJH, VB, VBK, VXF.
BMRN has underperformed the market in the last year with a return of -9.3%, while SPY returned +16.1%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in BMRN shares. However, BMRN has outperformed the market in the last 3 month and 2 week periods, returning +11.6% and +6.2%, while SPY returned +2.6% and +0.5%, respectively. This indicates BMRN has been having a stronger performance recently.
BMRN support price is $55.42 and resistance is $57.66 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BMRN shares will trade within this expected range on the day.
